Kornimate/medical-research-clean huggingface dataset:
the personal patient profile decision support for patients with bladder cancer

Conditions: Bladder Cancer

Summary: there is a pressing need to develop a personalized, value-based decisional tool for bladder cancer patients undergoing radical cystectomy (bladder removal) and urinary diversion to help them with communication with the physicians, shared decision making, and preparation for disease-management and follow-up care. the proposed intervention, the personal patient profile - bladder cancer (p3-bc), will be the first intervention to address these issues. results of this pilot randomized feasibility study will provide evidence of the feasibility and acceptability of the p3-bc and will guide further refinement of the tool for a larger experimental trial, with potential dissemination of the program via the internet and hand-held computing devices.


Eligibility criteria:
inclusion criteria: * patients: cystectomy for mibc and nmibc; * at least 18 years; * able to communicate in english; and * competent to give consent. exclusion criteria: - existence of other cancers or ongoing cancer treatment.

Keywords: bladder cancer shared decision making behavioral intervention urinary diversion
effects of individualized itbs on upper limb function after stroke

Conditions: Upper Extremity Paresis; Stroke

Summary: the primary objective of this clinical study is to assess the comparative efficacy of individualized intermittent theta burst stimulation (itbs) in contrast to standard itbs for individuals post-stroke experiencing upper limb impairment. the key inquiries addressed in this study encompass: enhancement of upper limb function: the primary investigation seeks to determine whether individualized itbs yields superior improvements in upper limb functionality compared to standard itbs. long-term effects: this study endeavors to explore the sustained effects of both individualized and standard itbs on upper limb function over an extended duration. neural mechanisms investigation: functional near-infrared spectroscopy (fnirs) will be employed to elucidate the neural mechanisms underlying the impact of itbs on the enhancement of upper limb function. post-stroke individuals with upper limb impairment will undergo pre-treatment assessments, including motor function evaluations and fnirs tests. subsequently, they will be randomized into three groups: individualized itbs, standard itbs, and sham stimulation. participants will undergo post-treatment assessments and follow-up evaluations. the research team aims to discern disparities in the efficacy of different itbs modalities. the central hypothesis posits that individualized itbs will demonstrate superior efficacy in enhancing post-stroke upper limb function, with sustained effects persisting for a minimum of one month.

this research constitutes a single-center, double-blind, randomized controlled study. upon enrollment, baseline information is established through the assessment of upper limb function using the fugl meyer assessment (fma), the modified rankin scale, the action research arm test (arat), and a handgrip test. additionally, functional near-infrared spectroscopy (fnirs) is employed to assess brain function, providing insights into the patient's motor network. participants in the study are randomly assigned to one of three groups: individualized itbs, standard itbs, and sham stimulation. all participants undergo physical therapy and occupational therapy tailored to their functional evaluation. after three weeks of treatment, participants are required to complete the aforementioned assessments, with a follow-up evaluation scheduled one month post-treatment.

Eligibility criteria:
inclusion criteria: 1. aging from 18-80 2. diagnosed as first-happened stroke,duration of the disease ranged from 1-3 months 3. upper extremity impairment 4. with mini-mental state examination\>15 5. agree to participate in this study and sigh the informed consent exclusion criteria: 1. with stroke history 2. have metal device within the body 3. with history of upper extremity trauma,fracture, and/or burn 4. serious conditions and can not finish the examination and treatment

Keywords: intermittent theta burst stimulation; upper extremity paresis; functional nearinfrared spectroscopy
quantitative genioglossal muscle strength in obstructive sleep apnea (osas)

Conditions: Obstructive Sleep Apnea

Summary: quantitative genioglossal muscle strength in obstructive sleep apnea (osas) defined in the clinical spectrum of subjects with snoring disturbance, oral appliance therapy responsive, and cpap responsive

to describe by statistical analysis the normal distribution domain of genioglossus muscle strength in each of the four clinical stages of sleep apnea; and, by regression analysis, to explore the possibility of an inverse relationship between decreasing genioglossus strength and progression of the clinical stages of osas. 1.3. to test the hypothesis that a "subpopulation of subject" exists within the clinical spectrum of osas, in whom decreasing strength of the genioglossus muscle may represent a common element in spite of differing possible pathophysiologic pathways leading to obstructive sleep apnea in man. 1.4. the major hypothesis of this proposal is thus that "genioglossal strength is inversely correlated with obstructive sleep apnea pathology."

Eligibility criteria:
inclusion criteria: * age 20-40 years inclusive bmi 18-25 non-smoking history and no current use for a minimum of 6 months no smokeless tobacco products (including e-cigarettes) for a minimum of 6 months no sleep snoring reported by subject and by bedroom "companion" self-described as active/athletic (i.e. regular hikes, walks, jogging, running, active sports, such as volleyball, soccer, etc.) self-described as healthy, with no known disease or recent illness self-completed epworth sleepiness scale of \<6 (johns, mw, a new method for measuring daytime sleepiness: the epworth sleepiness scale; sleep 14:450-5, 1991). physical examination mallampati score of class 1 (nuckton, tj, et al: physical examination: mallampati score as an independent predictor of osas; sleep 29: 903-908, 2006). exclusion criteria: -
evaluation of custom-designed dental storybook on the dental anxiety and behavior of children

Conditions: Child Behavior; Dental Anxiety

Summary: conventional behavior management techniques, namely: verbal communication and tell-show-do were used in the operatory for the participating children (group a). the children allocated in intervention group (group b) received a costume-designed storybook explaining the diagnosis and procedures of occlusal composite restoration


Eligibility criteria:
inclusion criteria: * • healthy children and children/parents can read and understand arabic. * the child needs an occlusal composite restoration. exclusion criteria: * children with special needs; children with a complete audiovisual impairment; children with * learning difficulties or mental retardation. * children who are not arabic speakers.

Keywords: dental storybook tell show do dental anxiety
open-label, multicenter extension study for patients completing treatment phase of a rigel-sponsored r935788 studies

Conditions: Rheumatoid Arthritis

Summary: the purpose of this new research study is to gain additional information about how safe and effective r935788 is over a longer period of time.


Eligibility criteria:
inclusion criteria: * patients must give written informed consent by signing an irb/ec-approved informed consent form (icf) prior to admission to this study * patients who are being treated in study c-788-006x * patients who completed studies c-788-010 or c-788-011 and did not withdraw due to adverse events * patients who withdrew from study c-788-010 at month 4 or month 5 because of a pre-defined lack of efficacy * females of childbearing potential must be fully informed of the potential for r788 to adversely affect the fetus and, if sexually active, must agree to use a well established method of birth control during the study (oral contraceptive, mechanical barrier, long acting hormonal agent). these patients must not be lactating and must have a negative pregnancy test at the time of entry and at each laboratory determination. exclusion criteria: * the patient has a history of, or a concurrent, clinically significant illness, medical condition (other than arthritis) or laboratory abnormality that, in the investigator's opinion, could affect the conduct of the study. specifically, excluded are patients with the following: 1. unresolved grade 2 or greater toxicity in a ra protocol studying r788 2. uncontrolled or poorly controlled hypertension; 3. recent (within past 2 months) serious surgery or infectious disease; 4. recent history (since enrollment in prior r788 study) of, or treatment for, a malignancy other than non-melanomatous skin cancer, or any history of lymphoma; 5. known to be positive for hepatitis b, hepatitis c, hiv or tuberculosis; 6. interstitial pneumonitis or active pulmonary infection; 7. known laboratory abnormalities: alt \> 1.2 x uln, creatinine \>1.5x uln, an anc \<2,500/mm3 or 2.5 x 109/l, lymphocyte count \< 600/mm3 or 0.6 x 109l, hgb \< 9 g/dl or 5 mmol/l, platelet count \<125,000/mm3 or 125 x 109/l are excluded. * the patient has a history of substance abuse, drug addiction or alcoholism. patients may consume up to 4 units of alcohol per week; however, alcohol should be avoided in the 72 hours prior to lab assessments. patients who cannot reliably comply with this should be excluded. a unit of alcohol is defined as the following: beer = 12 oz or 355 ml; wine = 5 oz or 148 ml; sweet dessert wine = 3 oz or 89 ml; 80 proof distilled spirits = 1.5 oz or 44 ml. * the patient is unable to report for clinical and laboratory monitoring as per protocol.

Keywords: ra
tight hemodynamic control in patients who are chronically on metoprolol

Conditions: Vascular Disease; Hypertension; Angina; Cardiac Disease

Summary: this study proposes to assess the effect of the standard of care, which is continuation of the pre op beta blocker dose into the post operative period compared to the administration of esmolol titrated to a pre determined target hr. the primary outcome will compare postoperative plasma levels of metoprolol in 2 cohorts in a group who has been continued on metoprolol (administrated via a nasogastric tube in npo patients) to a group who has been withdrawn from metoprolol but given an esmolol infusion titrated to hr. secondary outcomes will compare a) the hemodynamic responses, documenting the incidence of unplanned hypotension and bradycardia and b) to compare the effects of heart rate to the incidence of myocardial ischemia, arrhythmias, delirium and infarction.

the number of high-risk patients undergoing non-cardiac surgery has increased continuously over the last two decades. there is a paucity of data exist about the bioavailability of postoperative administrated beta-blockers. one study reported adequate plasma levels of propanolol after administration via nasogastric tube but not after oral administration in patient undergoing thyroid surgery.thus it is possible that patients maintained on oral beta blockers may in fact be experiencing a withdrawal syndrome. because of the importance of avoiding withdrawal of beta blockers, intravenous administration may be the only alternative in cases where oral administration fails to achieve adequate plasma levels perioperatively. furthermore, due to changes in pharmacodynamics, intravenous dosage may be the optimal way to achieve tight hemodynamic control. there is, however, no data on the post-operative hemodynamic effects of orally administered beta blockers in patients on chronic beta blockers.

Eligibility criteria:
patient inclusion criteria: * elective vascular surgery * any of the following co morbidities * diabetes * angina * congestive heart failure * a serum creatinine above 176 mmol/l * all patients must be on stable dose of oral metoprolol (≥ 30 days) * age ≥ 20 years and ≤ 80 years * written informed consent to participate to the study patient exclusion criteria: * inability to understand the study protocol * prior gastric surgery or small bowel resection * pacemaker ( since it precludes the measurement of st changes) * malabsorption syndromes * body mass index \ 35 * any patient with suspected of diagnosed cerebral vascular disease. (we chose to exclude cva patients due to the ongoing controversy about the increased incidence of stroke in patients have surgery and who are taking beta-blockers.)

Keywords: vascular surgery esmolol hemodynamic control
effects of l-carnitine supplementation on respiratory distress syndrome

Conditions: Premature Birth

Summary: the aim of the present study was to investigate the efficacy of l-carnitine therapy on the occurrence and prognosis of respiratory distress syndrome


Eligibility criteria:
inclusion criteria: * pregnant women between 30-37 weeks * singleton pregnancy exclusion criteria: * congenital malformed fetus * extreme premature
pilot study of organic nitrates on endothelial function in cad patients

Conditions: Coronary Artery Disease

Summary: organic nitrates increase levels of circulating endothelial progenitor cells (thum et al., arterioscler thromb vasc biol. 2007 apr;27(4):748-54). here, we want to test the effects of two different organic nitrates (petn, isdn) on number and function of endothelial progenitor cells and endothelial function.

in this pilot study we test the effects of two different organic nitrates (petn, isdn) on number and function of endothelial progenitor cells and endothelial function. these parameters will be measured before and after 14d of treatment.

Eligibility criteria:
inclusion criteria: * coronary artery disease, 2- or 3-vessel disease exclusion criteria: * acute myocardial infarction, acute heart failure, cancer, acute infections

Keywords: coronary artery disease
a cohort study of correlation between mast cells and prognosis in patients with acute myocardial infarction

Conditions: Inflammation; Acute ST Segment Elevation Myocardial Infarction; Prognosis

Summary: by including patients with acute myocardial infarction, mast cell markers were analyzed and the relationship between mast cells and patients with acute myocardial infarction was analyzed

percutaneous coronary intervention (pci) is the best way to improve the prognosis of patients with acute st-segment elevation myocardial infarction (stemi). however, ischemia reperfusion injury, inappropriate ventricular remodeling, and myocardial fibrosis may still be present in stemi after pci, which may be related to the inflammatory response in stemi. mast cells (mc), their degranulation products and induction of a series of inflammatory cytokines play an important role in the inflammatory response. the purpose of this study was to evaluate the relationship between mast cell markers (trypsin, chymotrypsin) levels and prognosis after direct pci in stemi patients. we prospectively and continuously included stemi patients undergoing standard therapy after direct pci. clinical data and blood samples were collected and followed up for 1 year to analyze mast cell markers and myocardial infarction size. as well as differences in echocardiography, markers of two-dimensional speck tracking techniques, inflammatory factors and major adverse cardiovascular events, to explore the relationship between mast cells and their products and ventricular remodeling and ischemia-reperfusion injury in stemi patients, and to provide new ideas for treatment and new basis for optimization of stemi treatment strategies.

Eligibility criteria:
inclusion criteria: * age above 18 years old, regardless of gender; * 2) meet stemi diagnostic criteria (diagnostic criteria: ischemic chest pain lasting ≥30min; st segment elevation of more than two adjacent leads or new left bundle branch block in ecg; with or without elevated myocardial markers) and receiving standard care for stemi. * 3) agree to and cooperate with the study exclusion criteria: * 1) the patient is taking or planning to take long-term oral or intravenous glucocorticoids (inhaled and topical hormones are allowed); * 2) allergic diseases, autoimmune diseases or malignant tumors. * 3) patients with metal implants or claustrophobia are not allowed to undergo an mri examination; * 4) pregnancy or lactation
the monaco initiative for concussion in motorsport pilots

Conditions: Brain Injuries; Concussion, Brain; Sport Injury

Summary: the study aims: * to observe a population particularly exposed by the past to brain trauma and concussion: motorsport pilots who are retired from a professional practice of motor sport; * to report results of their neuro-cognitive evaluations, * to determine if specific profiles emerge. * to evaluate potential consequences of these traumas' history at a cerebral, physical and psychological level. * to evaluate the contribution of the various examinations performed as part of a concussion assessment in routine care (eye-tracking, brain imaging, neuropsychological assessment).

the memory center of the rainier iii center and the department of nuclear medicine of the princess grace hospital are particularly aware of evaluation, management and monitoring of patients who have suffered brain trauma, or concussions, and the study of possible long-term consequences. they regularly receive patients, referred by neurologists or spontaneously coming for consultation, for whom the carrying out of a complete in-depth evaluation is recommended, because of their medical history and their personal history. in partnership with the "fédération internationale de l'automobile" (fia) and the "automobile club of monaco" (acm), the princess grace hospital team hopes ultimately to set up a screening campaign for traumatic brain injuries among a particularly exposed population: motorsports people. in this context, inspired by the work carried out by the cambridge university team (the rescue racer study) and the fia recommendations, the sponsor wishes to carry out an observational study with retired motor sportspeople. the objectives are to study a population particularly exposed by the past to brain trauma and concussion (who is retired from a professional practice of motor sport), to report results of their neuro-cognitive evaluations, and to determine if specific profiles emerge, to evaluate potential consequences of these traumas' history at a cerebral, physical and psychological level.

Eligibility criteria:
* men or women. * aged 18 years and older. * retired motor sport pilot (formula 1 or rally). * expressing a cognitive, memory, somatic, emotional complaint, sleep disorders or a concern following the practice of motorsport, that motivate carrying out of a memory assessment or a concussion assessment in routine care. * who are willing to participate in the study and give their written informed consent. * covered by a health insurance system.

Keywords: motorsport pilots concussions brain trauma traumatic brain injuries mri positron emission tomography (pet) scan video-oculography oculomotor behaviors
safety of cultured allogeneic adult umbilical cord derived mesenchymal stem cell intravenous infusion for aging frailty

Conditions: Frailty

Summary: this trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of aging frailty

studies have shown that stem cell treatment is safe and efficacious for the treatment of aging frailty. this patient funded trial aims to study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells (uc-mscs) for the treatment of frailty. patients with frailty will receive a single intravenous infusion of uc-mscs. the total dose will be 100 million cells. patients will be evaluated within one month pre treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for safety and efficacy.

Eligibility criteria:
inclusion criteria: * diagnosis of aging frailty * understanding and willingness to sign a written informed consent document exclusion criteria: * active infection * active cancer * chronic multisystem organ failure * pregnancy * clinically significant abnormalities on pre-treatment laboratory evaluation * medical condition that would (based on the opinion of the investigator) compromise patient's safety. * continued drug abuse * pre-menopausal women not using contraception * previous organ transplant * hypersensitivity to sulfur

Keywords: frailty stem cell treatment anti aging
prevention with chloroquine in health personnel exposed to infection with coronavirus disease 2019 (covid-19) (ts-covid)

Conditions: Covid19

Summary: the purpose of this study is to assess the efficacy and safety of chloroquine prophylaxis on the incidence of severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infections in healthcare workers exposed to patients with confirmed coronavirus disease 2019 (covid-19)

single arm study in which healthcare workers were actively invited to participate. possible participants were asked to complete a questionnaire to determine eligibility for study entry and to identify risk factors for infection, severe infection, or adverse events associated with chloroquine use. volunteers who meet the eligibility requirements received chloroquine 150mg base at days 0, 15, 30, 45, 60, 75. cumulative incidence and incidence rate of covid-19 at days 30,60 and 90 were calculated. presence of immunoglobulin g (igg) antibodies against sars-cov-2 was evaluated at the beginning, at the end and at any moment if they become infected with this virus. in addition, patients were asked to complete a survey evaluating adverse effects and covid-19 symptoms at day 0 and weeks 2,4,6,8,10, and 12.

Eligibility criteria:
inclusion criteria: * asymptomatic healthcare workers and contractors who work in fundacion valle del lili exclusion criteria: * to have two or more of the following symptoms 14 days previous to the initial assessment: cough, dyspnea, odynophagia, fatigue, weakness, fever \>38 degrees °c * history of close contact (less than two meters) with a person with probable or confirmed covid-19 without adequate protection during the last 14 days * history of one the following diseases in treatment at inclusion in the study: cardiac arrhythmias, epilepsy, kidney disease, seizures * treatment with concomitant medications: tamoxifen, quinine, cyclosporine, amiodarone, digoxine, anticonvulsivants * having recently taken chloroquine or hydroxychloroquine in the last two weeks * known hypersensitivity to chloroquine or hydroxychloroquine

Keywords: chloroquine covid-19 sars-cov-2 antibodies prophylaxis healthcare workers
stress, diurnal cortisol, and breast cancer survival

Conditions: Breast Cancer

Summary: the purpose of this study is to learn about the effects of stress on hormones, the relationship between these hormones and cancer progression.

the purpose of this study is to investigate stress and tonic activation of diurnal cortisol in aging metastatic breast cancer patients; feedback inhibition \& activation of cortisol; and stress-induced phasic activation of cortisol.

Eligibility criteria:
inclusion criteria: 1. diagnosis of recurrent or metastatic breast cancer. 2. karnofsky of 70% or greater. 3. proficient enough in english to be able to take questionnaires and participate in the required tasks. 4. living within the greater bay area. 5. age 35 or older . exclusion criteria: 1. positive supraclavicular lymph nodes as the only metastatic lesion at the time of initial diagnosis. 2. active cancers within the past 10 years other than breast cancer, basal cell or squamous cell carcinomas of the skin, or in situ cancer of the cervix. 3. any other serious medical condition that will effect short term survival 4. history of major psychiatric illness for which patient was hospitalized or medicated, with the exception of depression or anxiety 5. a diagnosis of diabetes.